A federal appeals court on Thursday again invalidated a patent protecting Teva Pharmaceutical’s big-selling drug, Copaxone, which can cost $60,000 a year.
Teva Ruling Clears Way for Generic Version of Multiple Sclerosis Drug
A federal appeals court on Thursday again invalidated a patent protecting Teva Pharmaceutical’s big-selling drug, Copaxone, which can cost $60,000 a year.
No comments:
Post a Comment